A Phase III, double blind, randomized, comparative study of the safety and immunogenicity of GSK Biologicals' Varilrix HSA-free varicella vaccine and Varilrix given as a 2 dose course in the second year of life

Trial Profile

A Phase III, double blind, randomized, comparative study of the safety and immunogenicity of GSK Biologicals' Varilrix HSA-free varicella vaccine and Varilrix given as a 2 dose course in the second year of life

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary)
  • Indications Varicella zoster virus infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline Biologicals
  • Most Recent Events

    • 27 Dec 2016 Status changed from recruiting to completed.
    • 19 Nov 2016 This trial has been completed in Germany, according to European Clinical Trials Database record.
    • 21 Sep 2016 This trial has been completed in the Estonia (30 Jun 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top